CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 6, 2006--Dyax Corp. (Nasdaq:DYAX) today announced the presentation of positive topline data from the Company’s completed open-label Phase II clinical trial, referred to as EDEMA2, with DX-88 for the treatment of hereditary angioedema (HAE). In this study DX-88 was well tolerated and successful in treating all types of attacks, including peripheral, abdominal and life-threatening laryngeal attacks, whether administered through the intravenous (IV) or subcutaneous (SQ) route of administration. DX-88 is being developed in a joint venture with Genzyme Corporation for the treatment of HAE, a debilitating and life-threatening inflammatory condition characterized by unpredictable attacks of severe pain and swelling.
